Post-traumatic stress disorder

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 16, 2021
U.S. Securities and Exchange Commission, MDD, Judgement, Clinical trial, Lists of diseases, Epilepsy, ET, Foundation Medicine, PTSD, Growth, CNS, Medicare Part D, SUNCT, Private Securities Litigation Reform Act, Woman, Safety, Review, ASSR, Central nervous system, Post-traumatic stress disorder, Company, Food, LinkedIn, Movement disorders, MAD, IND, FDA, Annual report, PMD, Depression, Investigational New Drug, ASO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Adult, Goal, Essential tremor, Trigeminal neuralgia, COVID-19, Conjunctiva, Pharmacokinetics, Investment, Exercise, Ageing, Dees, NASDAQ, Research, Autonomic, Central nervous system disease, SUNA, Brain, Twitter, EEG, GLOBE, Security (finance), Patient, SAD, PK, Animal, Cryptocurrency, Pharmaceutical industry, Lithium

The second quarter marked another inflection point for Praxis as we make progress toward being a diversified, late-stage, CNS focused company, said Marcio Souza, president and chief executive officer of Praxis.

Key Points: 
  • The second quarter marked another inflection point for Praxis as we make progress toward being a diversified, late-stage, CNS focused company, said Marcio Souza, president and chief executive officer of Praxis.
  • Praxis expects topline results from the ongoing PRAX-114 Phase 2/3 Aria Study for monotherapy treatment of MDD in the first half of 2022.
  • Praxis plans to initiate a PRAX-114 Phase 2 placebo-controlled study for treatment of post-traumatic stress disorder (PTSD) in the second half of 2021.
  • Second Quarter 2021 Financial Results:
    As of June 30, 2021, Praxis had $339.2 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020.

Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms

Retrieved on: 
Monday, August 16, 2021
Flash, PAM, U.S. Securities and Exchange Commission, MDD, Judgement, Anxiety, Population, Sexual dysfunction, Clinical trial, Praxis, Post-traumatic stress disorder, Goal, Central nervous system disease, Food, Essential tremor, Private Securities Litigation Reform Act, LinkedIn, Movement disorders, Insomnia, Brain, COVID-19, Twitter, Epilepsy, GABAA, Annual report, Security (finance), PTSD, Patient, CNS, PMD, Day 1, Depression, Safety, Woman, Menopause, Review, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today reported results from its PRAX-114 Phase 2a Part B proof-of-concept trial for treatment of perimenopausal depression (PMD) and announced plans to advance PRAX-114 to a Phase 2b study in women with menopausal and mood symptoms. Plans for the Phase 2b trial will be disclosed by the end of 2021.

Key Points: 
  • Part B of the Phase 2a study was an open-label, proof-of-concept assessment of a single daily dose of PRAX-114 60 mg suspension formulation administered for 14-days in an outpatient setting to women with PMD.
  • The objectives of the study were to examine safety and efficacy of PRAX-114 in PMD, a population of women with symptoms of menopause, including vasomotor symptoms (hot flashes), insomnia and sexual dysfunction, and mood symptoms, including depression and anxiety.
  • Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance.
  • Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Inagene and Aspiria team up to improve mental health care for post-secondary students

Retrieved on: 
Monday, August 16, 2021
Genetic testing, Ontario Student Assistance Program, Medical assistant, Anxiety, Ecosystem, CEO, Social isolation, Post-traumatic stress disorder, Lists of diseases, Company, Uncertainty, EAP, Mental health, COVID-19, Substance abuse, GLOBE, STAR, Risk, DNA, Parent, Citalopram, White, SAP, Organization, Health, PTSD, Telehealth, Veni, vidi, vici, Friends, Artificial intelligence, Employee assistance program, Student, Depression, Achievement Medal, CLIA, Prevalence, Medicine, Pharmaceutical industry, Tutoring

Together with Inagene, we can offer students a clearer path to the treatment of these conditions, providing both the tools and resources they need to better manage their mental health.

Key Points: 
  • Together with Inagene, we can offer students a clearer path to the treatment of these conditions, providing both the tools and resources they need to better manage their mental health.
  • Expanding our services to offer PGx testing helps us ensure that we are providing students with effective, personalized care to help speed recovery.
  • Poor medication experiences can also drive treatment adherence issues and present the risk of students resorting to self-medicating with street drugs or alcohol.
  • Through CloudMDs proprietary technology, the Company delivers quality healthcare through a holistic offering including hybrid primary care clinics, specialist care, telemedicine, mental health support, educational resources and artificial intelligence (AI).

Warriors Heart Co-Founder Tom Spooner opens up on The Dr. Drew Podcast about Veteran Healing Issues

Retrieved on: 
Monday, August 16, 2021
People, 7th Special Forces Group (United States), Today, US Army Small Ships Section, FOX, TBI, Green beret, Intensive outpatient program, KENS, IOP, WHY, Topical steroid withdrawal, Heart, Hope, Interview, SAN, Post-traumatic stress disorder, The Green Berets (film), Amazon Prime Video, Sober living houses, Hardship, HOW, Program, EMDR, Addiction, Army of the United States, Insurance, PTSD, Traumatic brain injury, Chicago Tribune, United States Army, Steel Panther, Woodworking, Trauma, Veteran, TO, The, KTTV, American City Business Journals, Warrior, Toy, Health insurance

SAN ANTONIO, Aug. 16, 2021 /PRNewswire-PRWeb/ -- To help his fellow warriors heal, Former Special Forces and Warriors Heart Co-Founder Tom Spooner opened up in a new interview with Dr. Drew Pinsky on The Dr. Drew Podcast .

Key Points: 
  • SAN ANTONIO, Aug. 16, 2021 /PRNewswire-PRWeb/ -- To help his fellow warriors heal, Former Special Forces and Warriors Heart Co-Founder Tom Spooner opened up in a new interview with Dr. Drew Pinsky on The Dr. Drew Podcast .
  • Speaking from the heart, Spooner described his military service, long-term recovery, the WHY and HOW behind creating Warriors Heart that is exclusively for frontline protectors (military, veterans, first responders, EMTs/Paramedics) and their new documentary : Warriors Heart: Warriors Healing Warriors (available on Amazon Prime Video).
  • When asked to describe their 42-day in-patient program, Spooner explained, "Everything we do at Warriors Heart is evidence-based.
  • There is a 24-hour Warriors Heart hotline (844-448-2567) answered by warriors.

VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 12, 2021
NMDA, MDD, Calendar, Major depressive disorder, PH94B, Lists of diseases, Epilepsy, Leadership, CNS, G&A, Board of directors, PH10, United, Safety, Johnson & Johnson, Industry, PALISADE, Awareness, Central nervous system, Post-traumatic stress disorder, Company, Food, LinkedIn, Mental health, Therapy, SEC, FDA, Annual report, Public relations, Depression, Regulation of tobacco by the U.S. Food and Drug Administration, Anxiety, Fast Track, PIN, COVID-19, U.S. Securities and Exchange Commission, Ajda, NDA, Suicidal ideation, Board, Cigna, Levodopa-induced dyskinesia, Trial of the century, NASDAQ, Social anxiety disorder, Research, SAN, Risk, Central nervous system disease, Russell, Program, Twitter, Neuropathic pain, GLOBE, Marketing, SAD, Probenecid, R, Pharmaceutical industry, Animal, Communications satellite

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today reported financial results for its fiscal year 2022 first quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • We expect to initiate that study in the U.S. before year end, said Shawn Singh, Chief Executive Officer of VistaGen.
  • Appointed Maggie FitzPatrick to our Board of Directors, bringing extensive leadership in healthcare consumer-focused engagement, marketing and public relations.
  • VistaGen will host a conference call and live audio webcast this afternoon at 2:00 p.m. Pacific Time to provide a corporate update and discuss its financial results for its fiscal year 2022 first quarter ended June 30, 2021.
  • We explicitly disclaim any obligation to update any forward-looking statements, other than as may be required by law.

Michael Flomenhaft Featured at Los Angeles Brain Mapping Conference

Retrieved on: 
Wednesday, August 11, 2021
General Health, Legal, Professional Services, Health, Pain, CA, Congress, Post-traumatic stress disorder, Neuroscience, Therapy, Knowledge, Chronic pain, Brain, RSD, TBI, Science, Injury, Brain damage, Concussion, Neuroanatomy, PLLC, Neuropsychology, Brain mapping, Lecture, Trauma, Annual, SBMT, Society, Nervous system, Physician, Surgeon, Spinal cord injury, Neuroimaging, Traumatic brain injury, CRPS, Complex regional pain syndrome, Medical imaging

Michael Flomenhaft, Esq., principal of New Yorks The Flomenhaft Law Firm, PLLC delivered two separate presentations at the Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT) in Los Angeles, CA.

Key Points: 
  • Michael Flomenhaft, Esq., principal of New Yorks The Flomenhaft Law Firm, PLLC delivered two separate presentations at the Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT) in Los Angeles, CA.
  • The organization has 200,000 scientists, engineers, surgeons, and physicians worldwide and is the flagship event for the SBMT.
  • The invitation for Mr. Flomenhaft to present at this conference was based on his recognized expertise in the field of neuroscience and its applications to civil cases such as traumatic brain injury (TBI) and Complex Regional Pain Syndrome (CRPS)/Reflex Sympathetic Dystrophy (RSD).
  • About The Flomenhaft Law Firm, PLLC
    Based in lower Manhattan, The Flomenhaft Law Firm, PLLC is renowned for its elite representation of victims of traumatic brain injury (TBI) including concussions and severe chronic pain .

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

Retrieved on: 
Wednesday, August 11, 2021
US Foods, COMPASS, Patient, PTSD, Food, Cancer, Annual report, CMPS, Private Securities Litigation Reform Act, Anorexia nervosa, Depression, U.S. Securities and Exchange Commission, GLOBE, Google, University of Oxford, G&A, Exercise, Forward-looking statement, Senior, TRD, Psychology, File, Social media, Neuroscience, Goal, Nasdaq, Post-traumatic stress disorder, Leadership, IIB, Research, Securities Act of 1933, Institute for National Security Studies (Israel), COVID, Intention, Institute of Psychiatry, Psychology and Neuroscience, Nature and Wildlife Discovery Center, CEO, LinkedIn, Review, Psilocybin, Verily, Digital, Terminology, Method, III, FDA, R, South London and Maudsley NHS Foundation Trust, Mental health, Hematology, Institute, SEC, University, Management, Pharmaceutical industry, Medicine, Life insurance

This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic.

Key Points: 
  • This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic.
  • We are well-positioned for recruitment to phase III, pending results from the phase IIb study, which are expected later this year.
  • The call will also be webcast on the investors section of the COMPASS Pathways website ( ir.compasspathways.com ) and archived for 30 days.
  • COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

Aptinyx Reports Second Quarter 2021 Financial Results and Business Highlights

Retrieved on: 
Tuesday, August 10, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, Connective tissue disease, COO, Administration, Investor, Baxter International, CEO, R, APTX, Caregiver, NMDA, Patient, University, BA, Trial of the century, Private Securities Litigation Reform Act, Chronic pain, U.S. Securities and Exchange Commission, Partnership, DSM-5, Security (finance), Enrollment, Annual report, Lewy body, Brain, Fibromyalgia, Government budget balance, Boston Consulting Group, COVID-19, Form 10-K, Lists of diseases, Twitter, Central nervous system, Inc., Doctor of Philosophy, Dementia, Baxter, Nasdaq, Post-traumatic stress disorder, Leadership, Total, Boston, FDA, Research, BM, Type C, MD, Research and development, ID, Pharmaceutical industry, Management, Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the second quarter of 2021 and provided key business updates.
  • Study 1 is expected to commence in the fourth quarter of 2021 and Study 2 is expected to commence in the first quarter of 2022.
  • Net Loss: For the second quarter of 2021, the net loss was $19.9 million compared to a net loss of $12.6 million for the second quarter of 2020.
  • ET to review its financial results and highlights for the second quarter of 2021 and subsequent period.

JNF-USA to Kick Off Jewish New Year in Spectacular Fashion with a Day of Giving from Coast to Coast

Retrieved on: 
Tuesday, August 10, 2021
City Winery, Food, Ecology, YouTube, Wine, The Next Decade (book), Post-traumatic stress disorder, Hudson River, Music, Tourism

Come for one of the best entertaining evenings you'll experience since the start of the pandemic.

Key Points: 
  • Come for one of the best entertaining evenings you'll experience since the start of the pandemic.
  • Whether you join us in-person or virtually, this is an event you don't want to miss."
  • To participate in JNF-USA's largest fundraising event of the year virtually, tune in live via YouTube or Facebook on Sunday, September 12, from 7-9pm ET.
  • JNF-USA is the leading philanthropic organization for Israel that supports critical environmental and nation building activities in Israel's north and south.

Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows Improvement in PTSD Symptoms and Decreased Inflammatory Response to Stress

Retrieved on: 
Tuesday, August 10, 2021
Post-traumatic stress disorder, Patient, FDA, ECOR, Child PTSD Symptom Scale, Interleukin 6, Naval Information Warfare Center Atlantic, Lists of diseases, Program, Biological Technologies Office (DARPA), DARPA, Disorder, PTSD, User experience, Sexual violence, Emory University, GLOBE, BTO, Spectrum, Woman, Death, NVN, Technology, Georgia Tech, Journal, Georgia Institute of Technology College of Computing, TNT, Man, Manuscript, Meat

Eight million American adults experience PTSD annually, and with limited FDA approved therapies, there is a large unmet medical need.

Key Points: 
  • Eight million American adults experience PTSD annually, and with limited FDA approved therapies, there is a large unmet medical need.
  • The disorder is more prominent in women, with about 10% of women and 4% of men developing PTSD at some point in their lives.
  • The study enrolled twenty patients suffering from PTSD.
  • Study participants were exposed to personalized traumatic scripts followed by an immediate stimulation by an active or sham non-invasive vagus nerve stimulator (nVNS).